Revision as of 12:12, 23 June 2024

Back to Top

Section editor
	Bhagirathbhai Dholaria, MBBS Vanderbilt University Nashville, TN, USA LinkedIn

Are you looking for a regimen but can't find it here? For placebo or observational studies in this condition, please visit this page. If you still can't find it, please let us know so we can add it!

We have moved How I Treat articles to a dedicated page.

16 regimens on this page 19 variants on this page

Guidelines

Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.

ESMO

2018: Willemze et al. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up PubMed
- 2013: Willemze et al. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up PubMed
- 2010: Willemze & Dreyling. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up PubMed
- 2009: Willemze & Dreyling. Primary cutaneous lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up PubMed
- 2008: Dummer & Dreyling. Primary cutaneous lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up PubMed
- 2007: Dummer. Primary cutaneous lymphomas: ESMO clinical recommendations for diagnosis, treatment and follow-up PubMed

NCCN

Upfront therapy

PUVA

PUVA: Psoralen & Ultra-Violet A

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Edelson et al. 1987	NR	Non-randomized (RT)
Whittaker et al. 2012 (EORTC 21011)	2003-2010	Phase 3 (C)	PUVA & Bexarotene	Did not meet primary endpoint of ORR

Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.

Chemotherapy

Methoxsalen (Uvadex) (see papers for details)

References

Edelson R, Berger C, Gasparro F, Jegasothy B, Heald P, Wintroub B, Vonderheid E, Knobler R, Wolff K, Plewig G, McKiernan G, Christiansen I, Oster M, Honigsmann H, Wilford H, Kokoschka E, Rehle T, Perez M, Stingl G, Laroche L. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy: preliminary results. N Engl J Med. 1987 Feb 5;316(6):297-303. link to original article PubMed
EORTC 21011: Whittaker S, Ortiz P, Dummer R, Ranki A, Hasan B, Meulemans B, Gellrich S, Knobler R, Stadler R, Karrasch M. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056). Br J Dermatol. 2012 Sep;167(3):678-87. link to original article PubMed NCT00056056

Topical therapy

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Kaye et al. 1989	1979-1987	Randomized, >20 pts (C)	CAV-E & RT	Did not meet primary endpoint of OS60

Usually consists of high-dose topical steroids or nitrogen mustards; see paper for details.

References

Kaye FJ, Bunn PA Jr, Steinberg SM, Stocker JL, Ihde DC, Fischmann AB, Glatstein EJ, Schechter GP, Phelps RM, Foss FM, Parlette HL, Anderson MJ, Sausville EA. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med. 1989 Dec 28;321(26):1784-90. link to original article PubMed

Relapsed or refractory

Alemtuzumab monotherapy

Regimen

Study	Evidence	Efficacy
Lundin et al. 2003	Phase 2	ORR: 55%

Targeted therapy

Alemtuzumab (Campath) 3 mg IV once on day 1, then increased to 10 mg IV once as soon as infusion-related reactions tolerated, then increased to 30 mg IV once as soon as infusion-related reactions tolerated, then 30 mg IV 3 days per week

Up to 12-week course

References

Lundin J, Hagberg H, Repp R, Cavallin-Ståhl E, Fredén S, Juliusson G, Rosenblad E, Tjønnfjord G, Wiklund T, Osterborg A. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood. 2003 Jun 1;101(11):4267-72. Epub 2003 Jan 23. link to original article contains dosing details in abstract PubMed

Belinostat monotherapy

Regimen

Study	Evidence	Efficacy
Foss et al. 2014 (PXD101-CLN-6)	Phase 2	ORR: 14%

Targeted therapy

Belinostat (Beleodaq) 1000 mg/m² IV over 30 minutes once per day on days 1 to 5

21-day cycles

References

PXD101-CLN-6: Foss F, Advani R, Duvic M, Hymes KB, Intragumtornchai T, Lekhakula A, Shpilberg O, Lerner A, Belt RJ, Jacobsen ED, Laurent G, Ben-Yehuda D, Beylot-Barry M, Hillen U, Knoblauch P, Bhat G, Chawla S, Allen LF, Pohlman B. A phase II trial of belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol. 2015 Mar;168(6):811-9. Epub 2014 Nov 17. link to original article contains dosing details in abstract PubMed NCT00274651

Bendamustine monotherapy

Regimen

Study	Evidence	Efficacy
Demaj et al. 2013 (BENTLY)	Phase 2	ORR: 50%

Chemotherapy

Bendamustine 120 mg/m² IV once per day on days 1 & 2

21-day cycle for 6 cycles

References

BENTLY: Damaj G, Gressin R, Bouabdallah K, Cartron G, Choufi B, Gyan E, Banos A, Jaccard A, Park S, Tournilhac O, Schiano-de Collela JM, Voillat L, Joly B, Le Gouill S, Saad A, Cony-Makhoul P, Vilque JP, Sanhes L, Schmidt-Tanguy A, Bubenheim M, Houot R, Diouf M, Marolleau JP, Béné MC, Martin A, Lamy T. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J Clin Oncol. 2013 Jan 1;31(1):104-10. Epub 2012 Oct 29. link to original article contains dosing details in manuscript PubMed NCT00959686

Bexarotene monotherapy

Regimen variant #1, 48 weeks

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Prince et al. 2017 (ALCANZA)	2012-2015	Phase 3 (C)	Brentuximab vedotin	Inferior PFS¹

¹Reported efficacy is based on the 2021 update.
Note: This dose is considered the target dose in ALCANZA.

Targeted therapy

Bexarotene (Targretin) 300 mg/m² PO once per day

48-week course

Regimen variant #2, indefinite

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Duvic et al. 2001a	1996-1998	Phase 2 (RT)		ORR: 55%
Duvic et al. 2001b	1997-02 to 1998-11	Phase 2/3 (E-RT-esc)	Bexarotene; 6.5 mg/m²/d	Superior ORR (primary endpoint)

Note: This dose is considered the optimal starting dose by Duvic et al. 2001a.

Targeted therapy

Bexarotene (Targretin) 300 mg/m² PO once per day

Continued indefinitely

References

Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P, Crowley C, Yocum RC; Bexarotene Worldwide Study Group. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol. 2001 May 1;19(9):2456-71. link to original article contains dosing details in manuscript PubMed
Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA, Yocum RC; Worldwide Bexarotene Study Group. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol. 2001 May;137(5):581-93. link to original article contains dosing details in manuscript PubMed
ALCANZA: Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Trotman J, Taylor K, Dalle S, Weichenthal M, Walewski J, Fisher D, Dréno B, Stadler R, Feldman T, Kuzel TM, Wang Y, Palanca-Wessels MC, Zagadailov E, Trepicchio WL, Zhang W, Lin HM, Liu Y, Huebner D, Little M, Whittaker S, Duvic M; ALCANZA study group. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017 Aug 5;390(10094):555-566. Epub 2017 Jun 7. link to original article contains dosing details in manuscript PubMed NCT01578499
1. Update: Horwitz SM, Scarisbrick JJ, Dummer R, Whittaker S, Duvic M, Kim YH, Quaglino P, Zinzani PL, Bechter O, Eradat H, Pinter-Brown L, Akilov OE, Geskin L, Sanches JA, Ortiz-Romero PL, Weichenthal M, Fisher DC, Walewski J, Trotman J, Taylor K, Dalle S, Stadler R, Lisano J, Bunn V, Little M, Prince HM. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data. Blood Adv. 2021 Dec 14;5(23):5098-5106. link to original article link to PMC article PubMed

Bexarotene & Pralatrexate

Regimen

Study	Dates of enrollment	Evidence	Efficacy
Duvic et al. 2017 (PDX-018)	2010-2015	Phase 1/2	ORR: 60%

Note: This dose is the MTD. Note that the abstract contains a typo for bexarotene dosing; the authors have been contacted.

Targeted therapy

Bexarotene (Targretin) 150 mg/m² PO once per day on days 1 to 28

Chemotherapy

Pralatrexate (Folotyn) 15 mg/m² IV once per day on days 1, 8, 15

28-day cycles

References

PDX-018: Duvic M, Kim YH, Zinzani PL, Horwitz SM. Results from a phase I/II open-label, dose-finding study of pralatrexate and oral bexarotene in patients with relapsed/refractory cutaneous T-cell lymphoma. Clin Cancer Res. 2017 Jul;23(14):3552-6. Epub 2017 Feb 6. link to original article contains dosing details in manuscript link to PMC article PubMed NCT01134341

Brentuximab vedotin monotherapy

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Kim et al. 2015 (SU-06212011-7946)	NR	Phase 2		OGRR: 70% (90% CI, 53-83)
Duvic et al. 2015 (MDACC 2010-0914)	2011-2013	Phase 2		ORR: 73% (95% CI, 60-86)
Prince et al. 2017 (ALCANZA)	2012-2015	Phase 3 (E-RT-switch-ooc)	Investigator's choice of: 1a. Bexarotene 1b. Methotrexate	Superior PFS¹ (secondary endpoint) Median PFS: 16.7 vs 3.5 mo (HR 0.27, 95% CI 0.17-0.43) Superior objective global response lasting at least 4 months (primary endpoint)

¹Reported efficacy is based on the 2021 update.

Antibody-drug conjugate therapy

Brentuximab vedotin (Adcetris) 1.8 mg/kg IV over 30 minutes once on day 1

21-day cycle for up to 16 cycles

References

SU-06212011-7946: Kim YH, Tavallaee M, Sundram U, Salva KA, Wood GS, Li S, Rozati S, Nagpal S, Krathen M, Reddy S, Hoppe RT, Nguyen-Lin A, Weng WK, Armstrong R, Pulitzer M, Advani RH, Horwitz SM. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and Sézary syndrome with variable CD30 expression level: A multi-institution collaborative project. J Clin Oncol. 2015 Nov 10;33(32):3750-8. Epub 2015 Jul 20. link to original article contains dosing details in manuscript link to PMC article PubMed NCT01396070
MDACC 2010-0914: Duvic M, Tetzlaff MT, Gangar P, Clos AL, Sui D, Talpur R. Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis. J Clin Oncol. 2015 Nov 10;33(32):3759-65. Epub 2015 Aug 10. link to original article contains dosing details in manuscript link to PMC article PubMed NCT01352520
ALCANZA: Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Trotman J, Taylor K, Dalle S, Weichenthal M, Walewski J, Fisher D, Dréno B, Stadler R, Feldman T, Kuzel TM, Wang Y, Palanca-Wessels MC, Zagadailov E, Trepicchio WL, Zhang W, Lin HM, Liu Y, Huebner D, Little M, Whittaker S, Duvic M; ALCANZA study group. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017 Aug 5;390(10094):555-566. Epub 2017 Jun 7. link to original article contains dosing details in manuscript PubMed NCT01578499
1. Update: Horwitz SM, Scarisbrick JJ, Dummer R, Whittaker S, Duvic M, Kim YH, Quaglino P, Zinzani PL, Bechter O, Eradat H, Pinter-Brown L, Akilov OE, Geskin L, Sanches JA, Ortiz-Romero PL, Weichenthal M, Fisher DC, Walewski J, Trotman J, Taylor K, Dalle S, Stadler R, Lisano J, Bunn V, Little M, Prince HM. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data. Blood Adv. 2021 Dec 14;5(23):5098-5106. link to original article link to PMC article PubMed

Denileukin diftitox monotherapy

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Olsen et al. 2001 (L4389-10)	NR	Phase 3 (E-RT-esc)	Denileukin diftitox; 9 mcg/kg	Did not meet primary endpoint of ORR
Prince et al. 2010 (L4389-11)	NR	Phase 3 (E-RT-esc)	1. Denileukin diftitox; 9 mcg/kg	Superior ORR (primary endpoint)
Prince et al. 2010 (L4389-11)	NR	Phase 3 (E-RT-esc)	2. Placebo	Superior PFS (secondary endpoint)

Note: Dose is that which was recommended in L4389-11 based on superior response. Up to 3 additional cycles allowed in L4389-10 for patients who had ongoing response.

Targeted therapy

Denileukin diftitox (Ontak) 18 mcg/kg IV over 15 to 60 minutes once per day on days 1 to 5

Supportive therapy

"Premedication with Acetaminophen (Tylenol) (650 mg in Olsen et al. 2001) and an antihistamine was required 30 to 60 minutes before each infusion" and could be used after infusions as needed.
Olsen et al. 2001 used Promethazine (Phenergan) 25 mg or Prochlorperazine (Compazine) 10 mg (route/schedule not specified) as needed for nausea.
Corticosteroid use was not allowed.

21-day cycles for up to 8 cycles (see note)

References

L4389-10: Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E, Jegasothy B, Wood G, Gordon M, Heald P, Oseroff A, Pinter-Brown L, Bowen G, Kuzel T, Fivenson D, Foss F, Glode M, Molina A, Knobler E, Stewart S, Cooper K, Stevens S, Craig F, Reuben J, Bacha P, Nichols J. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol. 2001 Jan 15;19(2):376-88. link to original article contains dosing details in manuscript PubMed
L4389-11: Prince HM, Duvic M, Martin A, Sterry W, Assaf C, Sun Y, Straus D, Acosta M, Negro-Vilar A. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2010 Apr 10;28(11):1870-7. Epub 2010 Mar 8. link to original article contains dosing details in manuscript PubMed NCT00050999
Meta-analysis: Duvic M, Geskin L, Prince HM. Duration of response in cutaneous T-cell lymphoma patients treated with denileukin diftitox: results from 3 phase III studies. Clin Lymphoma Myeloma Leuk. 2013 Aug;13(4):377-84. Epub 2013 Jun 14. link to original article PubMed

Lenalidomide monotherapy

Regimen

Study	Evidence	Efficacy
Querfeld et al. 2013 (NU 04H5)	Phase 2	ORR: 28%

Note: dose escalations only occurred if the prior dose was tolerated.

Targeted therapy

Lenalidomide (Revlimid) as follows:
- Cycle 1: 10 mg PO once per day on days 1 to 21
- Cycle 2: 15 mg PO once per day on days 1 to 21
- Cycle 3: 20 mg PO once per day on days 1 to 21
- Cycles 4 to 26: 25 mg PO once per day on days 1 to 21

28-day cycle for up to 26 cycles (2 years)

References

NU 04H5: Querfeld C, Rosen ST, Guitart J, Duvic M, Kim YH, Dusza SW, Kuzel TM. Results of an open-label multicenter phase II trial of lenalidomide monotherapy in refractory mycosis fungoides and Sezary syndrome. Blood. 2014 Feb 20;123(8):1159-66. Epub 2013 Dec 11. link to original article contains dosing details in manuscript PubMed NCT00466921

Methotrexate monotherapy

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Prince et al. 2017 (ALCANZA)	2012-2015	Phase 3 (C)	Brentuximab vedotin	Inferior PFS¹

¹Reported efficacy is based on the 2021 update.
Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.

Chemotherapy

Methotrexate (MTX) 5 to 50 mg PO once on day 1

7-day cycle for 48 cycles

References

Retrospective: Zackheim HS, Kashani-Sabet M, McMillan A. Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients. J Am Acad Dermatol. 2003 Nov;49(5):873-8. link to original article PubMed
ALCANZA: Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Trotman J, Taylor K, Dalle S, Weichenthal M, Walewski J, Fisher D, Dréno B, Stadler R, Feldman T, Kuzel TM, Wang Y, Palanca-Wessels MC, Zagadailov E, Trepicchio WL, Zhang W, Lin HM, Liu Y, Huebner D, Little M, Whittaker S, Duvic M; ALCANZA study group. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017 Aug 5;390(10094):555-566. Epub 2017 Jun 7. link to original article contains dosing details in manuscript PubMed NCT01578499
1. Update: Horwitz SM, Scarisbrick JJ, Dummer R, Whittaker S, Duvic M, Kim YH, Quaglino P, Zinzani PL, Bechter O, Eradat H, Pinter-Brown L, Akilov OE, Geskin L, Sanches JA, Ortiz-Romero PL, Weichenthal M, Fisher DC, Walewski J, Trotman J, Taylor K, Dalle S, Stadler R, Lisano J, Bunn V, Little M, Prince HM. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data. Blood Adv. 2021 Dec 14;5(23):5098-5106. link to original article link to PMC article PubMed

Mogamulizumab monotherapy

Regimen variant #1, 8-week course

Study	Evidence
Ogura et al. 2014 (KW-0761-004)	Phase 2

Targeted therapy

Mogamulizumab (Poteligeo) 1 mg/kg IV once on day 1

7-day cycle for 8 cycles

Regimen variant #2, indefinite

FDA-recommended dose

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Duvic et al. 2015 (KW-0761-001)	2009-NR	Phase 1/2
Kim et al. 2018 (MAVORIC)	2012-2016	Phase 3 (E-RT-switch-ooc)	Vorinostat	Superior PFS (primary endpoint)

Note: in KW-0761-001, a two-week "period of observation" was undertaken after cycle 1.

Targeted therapy

Mogamulizumab (Poteligeo) as follows:
- Cycle 1: 1 mg/kg IV once per day on days 1, 8, 15, 22
- Cycle 2 onwards: 1 mg/kg IV once per day on days 1 & 15

28-day cycles

References

KW-0761-004: Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, Fujimoto K, Yamamoto K, Miyamoto T, Uike N, Tanimoto M, Tsukasaki K, Ishizawa K, Suzumiya J, Inagaki H, Tamura K, Akinaga S, Tomonaga M, Ueda R. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014 Apr 10;32(11):1157-63. Epub 2014 Mar 10. link to original article contains dosing details in abstract PubMed NCT01192984
KW-0761-001: Duvic M, Pinter-Brown LC, Foss FM, Sokol L, Jorgensen JL, Challagundla P, Dwyer KM, Zhang X, Kurman MR, Ballerini R, Liu L, Kim YH. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood. 2015 Mar 19;125(12):1883-9. Epub 2015 Jan 20. link to original article contains dosing details in abstract link to PMC article PubMed NCT00888927
MAVORIC: Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M; MAVORIC Investigators. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018 Sep;19(9):1192-1204. Epub 2018 Aug 9. link to original article contains dosing details in abstract PubMed NCT01728805

Pralatrexate monotherapy

Regimen

Study	Evidence	Efficacy
Horwitz et al. 2012	Phase 2	RR: 45%

Note: Dose is that identified as recommended based on de-escalation strategy.

Chemotherapy

Pralatrexate (Folotyn) 15 mg/m² IV push once per day on days 1, 8, 15

Supportive therapy

Cyanocobalamin (Vitamin B12) 1 mg IM once every 8 to 10 weeks, within 10 weeks of treatment initiation
Folic acid (Folate) 1 mg PO once per day, starting at least 10 days prior to treatment initiation

28-day cycles

References

Horwitz SM, Kim YH, Foss F, Zain JM, Myskowski PL, Lechowicz MJ, Fisher DC, Shustov AR, Bartlett NL, Delioukina ML, Koutsoukos T, Saunders ME, O'Connor OA, Duvic M. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 2012 May 3;119(18):4115-22. Epub 2012 Mar 6. link to original article contains dosing details in manuscript PubMed

Romidepsin monotherapy

Regimen

Study	Dates of enrollment	Evidence	Efficacy
Piekarz et al. 2009 (NIH 01-C-0049_CTCL)	NR	Phase 2 (RT)	ORR: 34% (95% CI, 23-46)
Whittaker et al. 2010 (GPI-04-0001)	2005-2007	Phase 2 (RT)	ORR: 34% (95% CI, 25-45)

Targeted therapy

Romidepsin (Istodax) 14 mg/m² IV over 4 hours once per day on days 1, 8, 15

28-day cycle for up to 6 cycles; optional extension of treatment for patients with SD or better

References

NIH 01-C-0049_CTCL: Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH, Zain J, Prince HM, Leonard JP, Geskin LJ, Reeder C, Joske D, Figg WD, Gardner ER, Steinberg SM, Jaffe ES, Stetler-Stevenson M, Lade S, Fojo AT, Bates SE. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009 Nov 10;27(32):5410-7. Epub 2009 Oct 13. link to original article contains dosing details in manuscript link to PMC article PubMed NCT00007345
GPI-04-0001: Whittaker SJ, Demierre MF, Kim EJ, Rook AH, Lerner A, Duvic M, Scarisbrick J, Reddy S, Robak T, Becker JC, Samtsov A, McCulloch W, Kim YH. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010 Oct 10;28(29):4485-91. Epub 2010 Aug 9. link to original article contains dosing details in manuscript PubMed NCT00106431

Vorinostat monotherapy

Regimen

FDA-recommended dose

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Duvic et al. 2006	NR	Phase 2a (RT)		ORR: 24%
Olsen et al. 2007 (Merck 0683-001)	NR	Phase 2b (RT)		ORR: 30%
Kim et al. 2018 (MAVORIC)	2012-2016	Phase 3 (C)	Mogamulizumab	Inferior PFS

Note: Duvic et al. 2006 evaluated several different doses, but this is the one that "had the most favorable safety profile". To our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.

Targeted therapy

Vorinostat (Zolinza) 400 mg PO once per day

Continued indefinitely

References

Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VM, Frankel SR. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007 Jan 1;109(1):31-9. Epub 2006 Sep 7. Erratum in: Blood. 2007 Jun 15;109(12):5086. link to original article link to PMC article contains dosing details in abstract PubMed
Merck 0683-001: Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM, Duvic M. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007 Jul 20;25(21):3109-15. Epub 2007 Jun 18. link to original article contains dosing details in manuscript PubMed NCT00091559
1. Update: Duvic M, Olsen EA, Breneman D, Pacheco TR, Parker S, Vonderheid EC, Abuav R, Ricker JL, Rizvi S, Chen C, Boileau K, Gunchenko A, Sanz-Rodriguez C, Geskin LJ. Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma. Clin Lymphoma Myeloma. 2009 Dec;9(6):412-6. link to original article PubMed
MAVORIC: Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M; MAVORIC Investigators. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018 Sep;19(9):1192-1204. Epub 2018 Aug 9. link to original article contains dosing details in abstract PubMed NCT01728805

Relapsed or refractory, subsequent lines of treatment

Denileukin diftitox monotherapy

Regimen

Study	Evidence
Duvic et al. 2012	Non-randomized

Targeted therapy

Denileukin diftitox (Ontak) 18 mcg/kg IV once per day on days 1 to 5

21-day cycle for up to 8 cycles

References

Duvic M, Martin AG, Olsen EA, Fivenson DP, Prince HM. Efficacy and safety of denileukin diftitox retreatment in patients with relapsed cutaneous T-cell lymphoma. Leuk Lymphoma. 2013 Mar;54(3):514-9. Epub 2012 Sep 3. link to original article contains dosing details in abstract PubMed

Consolidation, all lines of therapy

Busulfan & Fludarabine, then allo HSCT

BuFlu: Busulfan & Fludarabine

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
de Masson et al. 2023 (CUTALLO)	2016-06-01 to 2022-03-03	Propensity score analysis (E-esc)	No transplant	Superior PFS (primary endpoint) Median PFS: 9 vs 3 mo (HR 0.38, 95% CI 0.21-0.69)

Chemotherapy

Fludarabine (Fludara) 30 mg/m² IV once per day for 3 days (days not specified)
Busulfan (Myleran) 3.2 mg/kg/day IV for 2 days (days not specified)

Immunotherapy

Allogeneic stem cells transfused on day 0

GVHD prophylaxis

Cyclosporine started on day -1, tapered on day +90 if no GVHD
Methotrexate (MTX) 15 mg/m² IV once on day +1, then 10 mg/m² IV once per day on days +3, +6, +11

One course

References

CUTALLO: de Masson A, Beylot-Barry M, Ram-Wolff C, Mear JB, Dalle S, d'Incan M, Ingen-Housz-Oro S, Orvain C, Abraham J, Dereure O, Charbonnier A, Cornillon J, Longvert C, Barete S, Boulinguez S, Wierzbicka-Hainaut E, Aubin F, Rubio MT, Bernard M, Schmidt-Tanguy A, Houot R, Pham-Ledard A, Michonneau D, Brice P, Labussière-Wallet H, Bouaziz JD, Grange F, Moins-Teisserenc H, Jondeau K, Michel L, Mourah S, Battistella M, Daguindau E, Loschi M, Picard A, Franck N, Maillard N, Huynh A, Nguyen S, Marçais A, Chaby G, Ceballos P, Le Corre Y, Maury S, Bay JO, Adamski H, Bachy E, Forcade E, Socié G, Bagot M, Chevret S, Peffault de Latour R; CUTALLO Investigators; Groupe Français d'Etude des Lymphomes Cutanés; Société Française de Greffe de Moëlle et Thérapie Cellulaire. Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study. Lancet. 2023 Jun 10;401(10392):1941-1950. Epub 2023 Apr 24. link to original article contains dosing details in supplement PubMed NCT02520908

Busulfan, Fludarabine, Thiotepa, then allo HSCT

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
de Masson et al. 2023 (CUTALLO)	2016-06-01 to 2022-03-03	Propensity score analysis (E-esc)	No transplant	Superior PFS (primary endpoint) Median PFS: 9 vs 3 mo (HR 0.38, 95% CI 0.21-0.69)

Note: this preparative regimen was intended for haploidentical HSCT.

Chemotherapy

Fludarabine (Fludara) 50 mg/m² IV once per day for 3 days (days not specified)
Busulfan (Myleran) 3.2 mg/kg/day IV for 3 days (days not specified)
Thiotepa (Tepadina) 5 mg/kg IV once (day not specified)

Immunotherapy

Allogeneic stem cells transfused on day 0

GVHD prophylaxis

Cyclophosphamide (Cytoxan) 50 mg/kg IV once per day on days +3 & +5
Cyclosporine started on day -1, tapered on day +90 if no GVHD
Mycophenolate mofetil (CellCept) 15 mg/kg PO three times per day until day +35

One course

References

CUTALLO: de Masson A, Beylot-Barry M, Ram-Wolff C, Mear JB, Dalle S, d'Incan M, Ingen-Housz-Oro S, Orvain C, Abraham J, Dereure O, Charbonnier A, Cornillon J, Longvert C, Barete S, Boulinguez S, Wierzbicka-Hainaut E, Aubin F, Rubio MT, Bernard M, Schmidt-Tanguy A, Houot R, Pham-Ledard A, Michonneau D, Brice P, Labussière-Wallet H, Bouaziz JD, Grange F, Moins-Teisserenc H, Jondeau K, Michel L, Mourah S, Battistella M, Daguindau E, Loschi M, Picard A, Franck N, Maillard N, Huynh A, Nguyen S, Marçais A, Chaby G, Ceballos P, Le Corre Y, Maury S, Bay JO, Adamski H, Bachy E, Forcade E, Socié G, Bagot M, Chevret S, Peffault de Latour R; CUTALLO Investigators; Groupe Français d'Etude des Lymphomes Cutanés; Société Française de Greffe de Moëlle et Thérapie Cellulaire. Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study. Lancet. 2023 Jun 10;401(10392):1941-1950. Epub 2023 Apr 24. link to original article contains dosing details in supplement PubMed NCT02520908

Fludarabine & Melphalan, then allo HSCT

FluMel: Fludarabine & Melphalan

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
de Masson et al. 2023 (CUTALLO)	2016-06-01 to 2022-03-03	Propensity score analysis (E-esc)	No transplant	Superior PFS (primary endpoint) Median PFS: 9 vs 3 mo (HR 0.38, 95% CI 0.21-0.69)

Chemotherapy

Fludarabine (Fludara) 30 mg/m² IV once per day for 3 days (days not specified)
Melphalan (Alkeran) 140 mg/m² IV once (day not specified)

Immunotherapy

Allogeneic stem cells transfused on day 0

GVHD prophylaxis

Cyclosporine started on day -1, tapered on day +90 if no GVHD
Methotrexate (MTX) 15 mg/m² IV once on day +1, then 10 mg/m² IV once per day on days +3, +6, +11

One course

References

CUTALLO: de Masson A, Beylot-Barry M, Ram-Wolff C, Mear JB, Dalle S, d'Incan M, Ingen-Housz-Oro S, Orvain C, Abraham J, Dereure O, Charbonnier A, Cornillon J, Longvert C, Barete S, Boulinguez S, Wierzbicka-Hainaut E, Aubin F, Rubio MT, Bernard M, Schmidt-Tanguy A, Houot R, Pham-Ledard A, Michonneau D, Brice P, Labussière-Wallet H, Bouaziz JD, Grange F, Moins-Teisserenc H, Jondeau K, Michel L, Mourah S, Battistella M, Daguindau E, Loschi M, Picard A, Franck N, Maillard N, Huynh A, Nguyen S, Marçais A, Chaby G, Ceballos P, Le Corre Y, Maury S, Bay JO, Adamski H, Bachy E, Forcade E, Socié G, Bagot M, Chevret S, Peffault de Latour R; CUTALLO Investigators; Groupe Français d'Etude des Lymphomes Cutanés; Société Française de Greffe de Moëlle et Thérapie Cellulaire. Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study. Lancet. 2023 Jun 10;401(10392):1941-1950. Epub 2023 Apr 24. link to original article contains dosing details in supplement PubMed NCT02520908

@@ Line 1: / Line 1: @@
-'''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]].'''
+<span id="BackToTop"></span>
+<div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px">
-Is there a regimen missing from this list?  Would you like to share a different dosage/schedule or an additional reference for a regimen?  Have you noticed an error?  Do you have an idea that will help the site grow to better meet your needs and the needs of many others?  You are [[How_to_contribute|invited to contribute to the site]].
+[[#top|Back to Top]]
+</div>
+{{#lst:Editorial board transclusions|tcl}}
+''Are you looking for a regimen but can't find it here? For placebo or observational studies in this condition, please visit [[Cutaneous T-cell lymphoma - null regimens|this page]]. If you still can't find it, please let us know so we can add it!''
+*''We have moved [[How I Treat]] articles to a dedicated page.''
 {| class="wikitable" style="float:right; margin-right: 5px;"
 |-
-|<div style="background-color: #66FF66; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]]  |?Regimen |limit=10000|format=sum}} regimens on this page</b></font></div>
+|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
-<div style="background-color: #66CCFF; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]]  |?Variant |limit=10000|format=sum}} variants on this page</b></font></div>
+<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
 |}
 {{TOC limit|limit=3}}
+=Guidelines=
+'''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.'''
+==ESMO==
+*'''2018:''' Willemze et al. [https://doi.org/10.1093/annonc/mdy133 Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://www.ncbi.nlm.nih.gov/pubmed/29878045 PubMed]
+**'''2013:''' Willemze et al. [https://doi.org/10.1093/annonc/mdt242 Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/23868906/ PubMed]
+**'''2010:''' Willemze & Dreyling. [https://doi.org/10.1093/annonc/mdq183 Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/20555075/ PubMed]
+**'''2009:''' Willemze & Dreyling. [https://doi.org/10.1093/annonc/mdp147 Primary cutaneous lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/19454428/ PubMed]
+**'''2008:''' Dummer & Dreyling. [https://doi.org/10.1093/annonc/mdn095 Primary cutaneous lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/18456777/ PubMed]
+**'''2007:''' Dummer. [https://doi.org/10.1093/annonc/mdm040 Primary cutaneous lymphomas: ESMO clinical recommendations for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/17491051/ PubMed]
-=Guidelines=
 ==NCCN==
-*[https://www.nccn.org/professionals/physician_gls/pdf/t-cell.pdf NCCN Guidelines - T-cell Lymphomas]
+*[https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1491 NCCN Guidelines - Primary Cutaneous Lymphomas]
+*[https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1483 NCCN Guidelines - T-cell Lymphomas]
-=Relapsed/refractory=
+=Upfront therapy=
+==PUVA==
+PUVA: '''<u>P</u>'''soralen & '''<u>U</u>'''ltra-'''<u>V</u>'''iolet '''<u>A</u>'''
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen===
+{| class="wikitable sortable" style="width: 100%; text-align:center;"
+!style="width: 20%"|Study
+!style="width: 20%"|Dates of enrollment
+!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 20%"|Comparator
+!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+|-
+|[https://doi.org/10.1056/NEJM198702053160603 Edelson et al. 1987]
+|NR
+| style="background-color:#91cf61" |Non-randomized (RT)
+| style="background-color:#d3d3d3" |
+| style="background-color:#d3d3d3" |
+|-
+|[https://doi.org/10.1111/j.1365-2133.2012.11156.x Whittaker et al. 2012 (EORTC 21011)]
+|2003-2010
+| style="background-color:#1a9851" |Phase 3 (C)
+|[[#PUVA_.26_Bexarotene_999|PUVA & Bexarotene]]
+| style="background-color:#ffffbf" |Did not meet primary endpoint of ORR
+|-
+|}
+''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.''
+<div class="toccolours" style="background-color:#b3e2cd">
+====Chemotherapy====
+*[[Methoxsalen (Uvadex)]] (see papers for details)
+</div></div>
+===References===
+# Edelson R, Berger C, Gasparro F, Jegasothy B, Heald P, Wintroub B, Vonderheid E, Knobler R, Wolff K, Plewig G, McKiernan G, Christiansen I, Oster M, Honigsmann H, Wilford H, Kokoschka E, Rehle T, Perez M, Stingl G, Laroche L. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy: preliminary results. N Engl J Med. 1987 Feb 5;316(6):297-303. [https://doi.org/10.1056/NEJM198702053160603 link to original article] [https://pubmed.ncbi.nlm.nih.gov/3543674/ PubMed]
+# '''EORTC 21011:''' Whittaker S, Ortiz P, Dummer R, Ranki A, Hasan B, Meulemans B, Gellrich S, Knobler R, Stadler R, Karrasch M. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056). Br J Dermatol. 2012 Sep;167(3):678-87. [https://doi.org/10.1111/j.1365-2133.2012.11156.x link to original article] [https://pubmed.ncbi.nlm.nih.gov/22924950/ PubMed] [https://clinicaltrials.gov/study/NCT00056056 NCT00056056]
-==Alemtuzumab (Campath) {{#subobject:cd1346|Regimen=1}}==
+==Topical therapy==
-{| class="wikitable" style="float:right; margin-left: 5px;"
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen===
+{| class="wikitable sortable" style="width: 100%; text-align:center;"
+!style="width: 20%"|Study
+!style="width: 20%"|Dates of enrollment
+!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 20%"|Comparator
+!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+|-
+|[https://doi.org/10.1056/NEJM198912283212603 Kaye et al. 1989]
+|1979-1987
+| style="background-color:#1a9851" |Randomized, >20 pts (C)
+|[[#CAV-E_.26_RT_999|CAV-E & RT]]
+| style="background-color:#ffffbf" |Did not meet primary endpoint of OS60
 |-
-|[[#top|back to top]]
 |}
+''Usually consists of high-dose topical steroids or nitrogen mustards; see paper for details.''
+</div></div>
+===References===
+# Kaye FJ, Bunn PA Jr, Steinberg SM, Stocker JL, Ihde DC, Fischmann AB, Glatstein EJ, Schechter GP, Phelps RM, Foss FM, Parlette HL, Anderson MJ, Sausville EA. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med. 1989 Dec 28;321(26):1784-90. [https://doi.org/10.1056/NEJM198912283212603 link to original article] [https://pubmed.ncbi.nlm.nih.gov/2594037/ PubMed]
+=Relapsed or refractory=
+==Alemtuzumab monotherapy {{#subobject:cd1346|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:7a3b21|Variant=1}}===
-{| border="1" style="text-align:center;" !align="left"
+{| class="wikitable" style="width: 60%; text-align:center;"
-|'''Study'''
+!style="width: 33%"|Study
-|[[Levels_of_Evidence#Evidence|'''Evidence''']]
+!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
 |[http://www.bloodjournal.org/content/101/11/4267.long Lundin et al. 2003]
-|style="background-color:#EEEE00"|Phase II
+|style="background-color:#91cf61"|Phase 2
+| style="background-color:#9ebcda" |ORR: 55%
 |-
 |}
-====Chemotherapy====
+<div class="toccolours" style="background-color:#b3e2cd">
-*[[Alemtuzumab (Campath)]] as follows:
+====Targeted therapy====
-**3 mg IV once on day 1, then
+*[[Alemtuzumab (Campath)]] 3 mg IV once on day 1, then increased to 10 mg IV once as soon as infusion-related reactions tolerated, then increased to 30 mg IV once as soon as infusion-related reactions tolerated, then 30 mg IV 3 days per week
-**Increased to 10 mg IV once as soon as infusion-related reactions tolerated, then
+'''Up to 12-week course'''
-**Increased to 30 mg IV once as soon as infusion-related reactions tolerated, then
+</div></div>
-**30 mg IV 3 days per week
-'''Up to 12 weeks of therapy'''
 ===References===
-# Lundin J, Hagberg H, Repp R, Cavallin-Ståhl E, Fredén S, Juliusson G, Rosenblad E, Tjønnfjord G, Wiklund T, Osterborg A. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood. 2003 Jun 1;101(11):4267-72. Epub 2003 Jan 23. [http://www.bloodjournal.org/content/101/11/4267.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12543862 PubMed]
+# Lundin J, Hagberg H, Repp R, Cavallin-Ståhl E, Fredén S, Juliusson G, Rosenblad E, Tjønnfjord G, Wiklund T, Osterborg A. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood. 2003 Jun 1;101(11):4267-72. Epub 2003 Jan 23. [http://www.bloodjournal.org/content/101/11/4267.long link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/12543862/ PubMed]
+==Belinostat monotherapy {{#subobject:f8519|Regimen=1}}==
-==Belinostat (Beleodaq) {{#subobject:f8519|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
-{| class="wikitable" style="float:right; margin-left: 5px;"
-|-
-|[[#top|back to top]]
-|}
 ===Regimen {{#subobject:693804|Variant=1}}===
-{| border="1" style="text-align:center;" !align="left"
+{| class="wikitable" style="width: 60%; text-align:center;"
-|'''Study'''
+!style="width: 33%"|Study
-|[[Levels_of_Evidence#Evidence|'''Evidence''']]
+!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
-|[http://onlinelibrary.wiley.com/doi/10.1111/bjh.13222/full Foss et al. 2014]
+|[https://doi.org/10.1111/bjh.13222 Foss et al. 2014 (PXD101-CLN-6)]
-|style="background-color:#EEEE00"|Phase II
+|style="background-color:#91cf61"|Phase 2
+| style="background-color:#88419d; color:white |ORR: 14%
 |-
 |}
-====Chemotherapy====
+<div class="toccolours" style="background-color:#b3e2cd">
+====Targeted therapy====
 *[[Belinostat (Beleodaq)]] 1000 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 to 5
 '''21-day cycles'''
+</div></div>
 ===References===
 <!-- # '''Abstract:''' Pohlman, Brad, Advani, Ranjana, Duvic, Madeleine, Hymes, Kenneth B., Intragumtornchai, Tanin, Lekhakula, Arnuparp, Shpilberg, Ofer, Lerner, Adam, Ben-Yehuda, Dina, beylot-Barry, Marie, Hillen, Uwe, Fagerberg, Jan, Foss, Francine M. Final Results of a Phase II Trial of Belinostat (PXD101) in Patients with Recurrent or Refractory Peripheral or Cutaneous T-Cell Lymphoma. ASH Annual Meeting Abstracts 2009 114: 920. [http://abstracts.hematologylibrary.org/cgi/content/abstract/114/22/920 link to abstract] -->
-# Foss F, Advani R, Duvic M, Hymes KB, Intragumtornchai T, Lekhakula A, Shpilberg O, Lerner A, Belt RJ, Jacobsen ED, Laurent G, Ben-Yehuda D, Beylot-Barry M, Hillen U, Knoblauch P, Bhat G, Chawla S, Allen LF, Pohlman B. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol. 2015 Mar;168(6):811-9. Epub 2014 Nov 17. [http://onlinelibrary.wiley.com/doi/10.1111/bjh.13222/full link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25404094 PubMed]
+# '''PXD101-CLN-6:''' Foss F, Advani R, Duvic M, Hymes KB, Intragumtornchai T, Lekhakula A, Shpilberg O, Lerner A, Belt RJ, Jacobsen ED, Laurent G, Ben-Yehuda D, Beylot-Barry M, Hillen U, Knoblauch P, Bhat G, Chawla S, Allen LF, Pohlman B. A phase II trial of belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol. 2015 Mar;168(6):811-9. Epub 2014 Nov 17. [https://doi.org/10.1111/bjh.13222 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/25404094/ PubMed] [https://clinicaltrials.gov/study/NCT00274651 NCT00274651]
+==Bendamustine monotherapy {{#subobject:1a5a99|Regimen=1}}==
-==Bendamustine {{#subobject:1a5a99|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
-{| class="wikitable" style="float:right; margin-left: 5px;"
-|-
-|[[#top|back to top]]
-|}
 ===Regimen {{#subobject:44f094|Variant=1}}===
-{| border="1" style="text-align:center;" !align="left"
+{| class="wikitable" style="width: 60%; text-align:center;"
-|'''Study'''
+!style="width: 33%"|Study
-|[[Levels_of_Evidence#Evidence|'''Evidence''']]
+!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
-|[http://jco.ascopubs.org/content/31/1/104.long Demaj et al. 2013 (BENTLY)]
+|[https://doi.org/10.1200/jco.2012.43.7285 Demaj et al. 2013 (BENTLY)]
-|style="background-color:#EEEE00"|Phase II
+|style="background-color:#91cf61"|Phase 2
+| style="background-color:#8c96c6" |ORR: 50%
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
-''Note: these infusion instructions are for the Treanda formulation, which was discontinued on 3/31/2016.''
+*[[Bendamustine]] 120 mg/m<sup>2</sup> IV once per day on days 1 & 2
-*[[Bendamustine]] 120 mg/m<sup>2</sup> IV over 30 to 60 minutes once per day on days 1 & 2
+'''21-day cycle for 6 cycles'''
+</div></div>
-'''3-week cycle for 6 cycles'''
 ===References===
-# Damaj G, Gressin R, Bouabdallah K, Cartron G, Choufi B, Gyan E, Banos A, Jaccard A, Park S, Tournilhac O, Schiano-de Collela JM, Voillat L, Joly B, Le Gouill S, Saad A, Cony-Makhoul P, Vilque JP, Sanhes L, Schmidt-Tanguy A, Bubenheim M, Houot R, Diouf M, Marolleau JP, Béné MC, Martin A, Lamy T. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J Clin Oncol. 2013 Jan 1;31(1):104-10. Epub 2012 Oct 29. [http://jco.ascopubs.org/content/31/1/104.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23109692 PubMed]
+# '''BENTLY:''' Damaj G, Gressin R, Bouabdallah K, Cartron G, Choufi B, Gyan E, Banos A, Jaccard A, Park S, Tournilhac O, Schiano-de Collela JM, Voillat L, Joly B, Le Gouill S, Saad A, Cony-Makhoul P, Vilque JP, Sanhes L, Schmidt-Tanguy A, Bubenheim M, Houot R, Diouf M, Marolleau JP, Béné MC, Martin A, Lamy T. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J Clin Oncol. 2013 Jan 1;31(1):104-10. Epub 2012 Oct 29. [https://doi.org/10.1200/jco.2012.43.7285 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/23109692/ PubMed] [https://clinicaltrials.gov/study/NCT00959686 NCT00959686]
+==Bexarotene monotherapy {{#subobject:feb851|Regimen=1}}==
-==Bexarotene (Targretin) {{#subobject:feb851|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
-{| class="wikitable" style="float:right; margin-left: 5px;"
+===Regimen variant #1, 48 weeks {{#subobject:67ef8a|Variant=1}}===
+{| class="wikitable sortable" style="width: 100%; text-align:center;"
+!style="width: 20%"|Study
+!style="width: 20%"|Dates of enrollment
+!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 20%"|Comparator
+!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+|-
+|[https://doi.org/10.1016/S0140-6736(17)31266-7 Prince et al. 2017 (ALCANZA)]
+|2012-2015
+|style="background-color:#1a9851"|Phase 3 (C)
+|[[#Brentuximab_vedotin_monotherapy|Brentuximab vedotin]]
+|style="background-color:#d73027"|Inferior PFS<sup>1</sup>
 |-
-|[[#top|back to top]]
 |}
+''<sup>1</sup>Reported efficacy is based on the 2021 update.''<br>
-===Regimen {{#subobject:67ef8a|Variant=1}}===
+''Note: This dose is considered the target dose in ALCANZA.''
-{| border="1" style="text-align:center;" !align="left"
+<div class="toccolours" style="background-color:#b3e2cd">
-|'''Study'''
+====Targeted therapy====
-|[[Levels_of_Evidence#Evidence|'''Evidence''']]
+*[[Bexarotene (Targretin)]] 300 mg/m<sup>2</sup> PO once per day
+'''48-week course'''
+</div></div><br>
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen variant #2, indefinite {{#subobject:68je8a|Variant=1}}===
+{| class="wikitable sortable" style="width: 100%; text-align:center;"
+!style="width: 20%"|Study
+!style="width: 20%"|Dates of enrollment
+!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 20%"|Comparator
+!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+|-
+|[https://doi.org/10.1200/jco.2001.19.9.2456 Duvic et al. 2001a]
+|1996-1998
+|style="background-color:#91cf61"|Phase 2 (RT)
+|style="background-color:#d3d3d3"|
+| style="background-color:#9ebcda" |ORR: 55%
 |-
-|[http://jco.ascopubs.org/content/19/9/2456.long Duvic et al. 2001a]
+|[http://archderm.jamanetwork.com/article.aspx?articleid=478334 Duvic et al. 2001b]
-|style="background-color:#EEEE00"|Phase II
+|1997-02 to 1998-11
+|style="background-color:#1a9851"|Phase 2/3 (E-RT-esc)
+|[[#Bexarotene_monotherapy|Bexarotene]]; 6.5 mg/m<sup>2</sup>/d
+| style="background-color:#1a9850" |Superior ORR (primary endpoint)
 |-
 |}
+''Note: This dose is considered the optimal starting dose by Duvic et al. 2001a.''
-''This dose is considered the optimal starting dose by Duvic et al. 2001a.''
+<div class="toccolours" style="background-color:#b3e2cd">
-====Chemotherapy====
+====Targeted therapy====
 *[[Bexarotene (Targretin)]] 300 mg/m<sup>2</sup> PO once per day
+'''Continued indefinitely'''
-'''Duration not specified; presumptively until progression or intolerance'''
+</div></div>
 ===References===
-# Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P, Crowley C, Yocum RC; Bexarotene Worldwide Study Group. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol. 2001 May 1;19(9):2456-71. [http://jco.ascopubs.org/content/19/9/2456.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11331325 PubMed]
+# Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P, Crowley C, Yocum RC; Bexarotene Worldwide Study Group. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol. 2001 May 1;19(9):2456-71. [https://doi.org/10.1200/jco.2001.19.9.2456 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/11331325/ PubMed]
-# Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA, Yocum RC; Worldwide Bexarotene Study Group. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol. 2001 May;137(5):581-93. [http://archderm.jamanetwork.com/article.aspx?articleid=478334 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11346336 PubMed]
+# Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA, Yocum RC; Worldwide Bexarotene Study Group. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol. 2001 May;137(5):581-93. [http://archderm.jamanetwork.com/article.aspx?articleid=478334 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/11346336/ PubMed]
+# '''ALCANZA:''' Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Trotman J, Taylor K, Dalle S, Weichenthal M, Walewski J, Fisher D, Dréno B, Stadler R, Feldman T, Kuzel TM, Wang Y, Palanca-Wessels MC, Zagadailov E, Trepicchio WL, Zhang W, Lin HM, Liu Y, Huebner D, Little M, Whittaker S, Duvic M; ALCANZA study group. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017 Aug 5;390(10094):555-566. Epub 2017 Jun 7. [https://doi.org/10.1016/S0140-6736(17)31266-7 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/28600132/ PubMed] [https://clinicaltrials.gov/study/NCT01578499 NCT01578499]
+##'''Update:''' Horwitz SM, Scarisbrick JJ, Dummer R, Whittaker S, Duvic M, Kim YH, Quaglino P, Zinzani PL, Bechter O, Eradat H, Pinter-Brown L, Akilov OE, Geskin L, Sanches JA, Ortiz-Romero PL, Weichenthal M, Fisher DC, Walewski J, Trotman J, Taylor K, Dalle S, Stadler R, Lisano J, Bunn V, Little M, Prince HM. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data. Blood Adv. 2021 Dec 14;5(23):5098-5106. [https://doi.org/10.1182/bloodadvances.2021004710 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9153035/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/34507350/ PubMed]
 ==Bexarotene & Pralatrexate {{#subobject:8d4e8d|Regimen=1}}==
-{| class="wikitable" style="float:right; margin-left: 5px;"
+<div class="toccolours" style="background-color:#eeeeee">
-|-
-|[[#top|back to top]]
-|}
 ===Regimen {{#subobject:53ada8|Variant=1}}===
-{| border="1" style="text-align:center;" !align="left"
+{| class="wikitable sortable" style="width: 80%; text-align:center;"
-|'''Study'''
+!style="width: 25%"|Study
-|[[Levels_of_Evidence#Evidence|'''Evidence''']]
+!style="width: 25%"|Dates of enrollment
+!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
-|[http://clincancerres.aacrjournals.org/content/23/14/3552 Duvic et al. 2017]
+|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5511551/ Duvic et al. 2017 (PDX-018)]
-|style="background-color:#EEEE00"|Phase I/II
+|2010-2015
+|style="background-color:#91cf61"|Phase 1/2
+| style="background-color:#9ebcda" |ORR: 60%
 |-
 |}
-''This dose is the MTD. Note that the abstract contains a typo for bexarotene dosing; the authors have been contacted.''
+''Note: This dose is the MTD. Note that the abstract contains a typo for bexarotene dosing; the authors have been contacted.''
+<div class="toccolours" style="background-color:#b3e2cd">
+====Targeted therapy====
+*[[Bexarotene (Targretin)]] 150 mg/m<sup>2</sup> PO once per day on days 1 to 28
 ====Chemotherapy====
-*[[Bexarotene (Targretin)]] 150 mg/m<sup>2</sup> PO once per day
 *[[Pralatrexate (Folotyn)]] 15 mg/m<sup>2</sup> IV once per day on days 1, 8, 15
+'''28-day cycles'''
-'''4-week cycles'''
+</div></div>
 ===References===
-# Duvic M, Kim YH, Zinzani PL, Horwitz SM. Results from a phase I/II open-label, dose-finding study of pralatrexate and oral bexarotene in patients with relapsed/refractory cutaneous T-cell lymphoma. Clin Cancer Res. 2017 Jul;23(14):3552-6. Epub 2017 Feb 6. [http://clincancerres.aacrjournals.org/content/23/14/3552 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28167509 PubMed]
+# '''PDX-018:''' Duvic M, Kim YH, Zinzani PL, Horwitz SM. Results from a phase I/II open-label, dose-finding study of pralatrexate and oral bexarotene in patients with relapsed/refractory cutaneous T-cell lymphoma. Clin Cancer Res. 2017 Jul;23(14):3552-6. Epub 2017 Feb 6. [http://clincancerres.aacrjournals.org/content/23/14/3552 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5511551/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/28167509/ PubMed] [https://clinicaltrials.gov/study/NCT01134341 NCT01134341]
+==Brentuximab vedotin monotherapy {{#subobject:2781ab|Regimen=1}}==
-==Brentuximab vedotin (Adcetris) {{#subobject:2781ab|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
-{| class="wikitable" style="float:right; margin-left: 5px;"
+===Regimen {{#subobject:34eb6|Variant=1}}===
+{| class="wikitable sortable" style="width: 100%; text-align:center;"
+!style="width: 20%"|Study
+!style="width: 20%"|Dates of enrollment
+!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 20%"|Comparator
+!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 |-
-|[[#top|back to top]]
+|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089160/ Kim et al. 2015 (SU-06212011-7946)]
-|}
+|NR
+|style="background-color:#91cf61"|Phase 2
-===Regimen {{#subobject:34eb6|Variant=1}}===
+|style="background-color:#d3d3d3"|
-{| border="1" style="text-align:center;" !align="left"
+| style="background-color:#bfd3e6" |OGRR: 70% (90% CI, 53-83)
-|'''Study'''
-|[[Levels_of_Evidence#Evidence|'''Evidence''']]
 |-
-|[http://jco.ascopubs.org/content/33/32/3750.full Kim et al. 2015]
+|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737859/ Duvic et al. 2015 (MDACC 2010-0914)]
-|style="background-color:#EEEE00"|Phase II
+|2011-2013
+|style="background-color:#91cf61"|Phase 2
+|style="background-color:#d3d3d3"|
+| style="background-color:#bfd3e6" |ORR: 73% (95% CI, 60-86)
 |-
-|[http://jco.ascopubs.org/content/33/32/3759.full Duvic et al. 2015]
+|[https://doi.org/10.1016/S0140-6736(17)31266-7 Prince et al. 2017 (ALCANZA)]
-|style="background-color:#EEEE00"|Phase II
+|2012-2015
+|style="background-color:#1a9851"|Phase 3 (E-RT-switch-ooc)
+|Investigator's choice of:<br>1a. [[#Bexarotene_monotherapy|Bexarotene]]<br>1b. [[#Methotrexate_monotherapy|Methotrexate]]
+|style="background-color:#1a9850"|Superior PFS<sup>1</sup> (secondary endpoint)<br>Median PFS: 16.7 vs 3.5 mo<br>(HR 0.27, 95% CI 0.17-0.43)<br><br>Superior objective global response lasting at least 4 months (primary endpoint)
 |-
 |}
-====Chemotherapy====
+''<sup>1</sup>Reported efficacy is based on the 2021 update.''
+<div class="toccolours" style="background-color:#b3e2cd">
+====Antibody-drug conjugate therapy====
 *[[Brentuximab vedotin (Adcetris)]] 1.8 mg/kg IV over 30 minutes once on day 1
+'''21-day cycle for up to 16 cycles'''
-'''3-week cycle for up to 16 infusions'''
+</div></div>
 ===References===
 <!-- Presented in part at the 54th Annual Meeting of the American Society of Hematology, December 8-11, 2012, Atlanta, GA, the 56th Annual Meeting of the American Society of Hematology, December 6-9, 2014, San Francisco, CA, and the 72nd Annual Meeting of the Society for Investigative Dermatology, May 9-12, 2012, Raleigh, NC. -->
-# Kim YH, Tavallaee M, Sundram U, Salva KA, Wood GS, Li S, Rozati S, Nagpal S, Krathen M, Reddy S, Hoppe RT, Nguyen-Lin A, Weng WK, Armstrong R, Pulitzer M, Advani RH, Horwitz SM. Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. J Clin Oncol. 2015 Nov 10;33(32):3750-8. Epub 2015 Jul 20. [http://jco.ascopubs.org/content/33/32/3750.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26195720 PubMed]
+# '''SU-06212011-7946:''' Kim YH, Tavallaee M, Sundram U, Salva KA, Wood GS, Li S, Rozati S, Nagpal S, Krathen M, Reddy S, Hoppe RT, Nguyen-Lin A, Weng WK, Armstrong R, Pulitzer M, Advani RH, Horwitz SM. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and Sézary syndrome with variable CD30 expression level: A multi-institution collaborative project. J Clin Oncol. 2015 Nov 10;33(32):3750-8. Epub 2015 Jul 20. [https://doi.org/10.1200/jco.2014.60.3969 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089160/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/26195720/ PubMed] [https://clinicaltrials.gov/study/NCT01396070 NCT01396070]
 <!-- Presented in part at the 54th Annual Meeting of the American Society of Hematology, Atlanta, GA, December 8-11, 2012; the 55th Annual Meeting of the American Society of Hematology, New Orleans, LA, December 7-10, 2013; the 75th Annual Meeting of the Society of Investigative Dermatology, Raleigh, NC, May 9-12, 2012; the International Investigative Dermatology Meeting, Edinburgh, United Kingdom, May 8-11, 2013; the 2nd World Congress Cutaneous Lymphoma, Berlin, Germany, February 6-9, 2013; and the 6th Annual T-Cell Lymphoma Forum, San Francisco, CA, January 23-25, 2014. -->
-# Duvic M, Tetzlaff MT, Gangar P, Clos AL, Sui D, Talpur R. Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis. J Clin Oncol. 2015 Nov 10;33(32):3759-65. Epub 2015 Aug 10. [http://jco.ascopubs.org/content/33/32/3759.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26261247 PubMed]
+# '''MDACC 2010-0914:''' Duvic M, Tetzlaff MT, Gangar P, Clos AL, Sui D, Talpur R. Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis. J Clin Oncol. 2015 Nov 10;33(32):3759-65. Epub 2015 Aug 10. [https://doi.org/10.1200/jco.2014.60.3787 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737859/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/26261247/ PubMed] [https://clinicaltrials.gov/study/NCT01352520 NCT01352520]
+# '''ALCANZA:''' Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Trotman J, Taylor K, Dalle S, Weichenthal M, Walewski J, Fisher D, Dréno B, Stadler R, Feldman T, Kuzel TM, Wang Y, Palanca-Wessels MC, Zagadailov E, Trepicchio WL, Zhang W, Lin HM, Liu Y, Huebner D, Little M, Whittaker S, Duvic M; ALCANZA study group. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017 Aug 5;390(10094):555-566. Epub 2017 Jun 7. [https://doi.org/10.1016/S0140-6736(17)31266-7 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/28600132/ PubMed] [https://clinicaltrials.gov/study/NCT01578499 NCT01578499]
-==Denileukin Diftitox (Ontak) {{#subobject:751a63|Regimen=1}}==
+##'''Update:''' Horwitz SM, Scarisbrick JJ, Dummer R, Whittaker S, Duvic M, Kim YH, Quaglino P, Zinzani PL, Bechter O, Eradat H, Pinter-Brown L, Akilov OE, Geskin L, Sanches JA, Ortiz-Romero PL, Weichenthal M, Fisher DC, Walewski J, Trotman J, Taylor K, Dalle S, Stadler R, Lisano J, Bunn V, Little M, Prince HM. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data. Blood Adv. 2021 Dec 14;5(23):5098-5106. [https://doi.org/10.1182/bloodadvances.2021004710 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9153035/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/34507350/ PubMed]
-{| class="wikitable" style="float:right; margin-left: 5px;"
+==Denileukin diftitox monotherapy {{#subobject:751a63|Regimen=1}}==
-|-
+<div class="toccolours" style="background-color:#eeeeee">
-|[[#top|back to top]]
-|}
 ===Regimen {{#subobject:4e103c|Variant=1}}===
-{| border="1" style="text-align:center;" !align="left"
+{| class="wikitable sortable" style="width: 100%; text-align:center;"
-|'''Study'''
+!style="width: 20%"|Study
-|[[Levels_of_Evidence#Evidence|'''Evidence''']]
+!style="width: 20%"|Dates of enrollment
-|'''Comparator'''
+!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
-|[[Levels_of_Evidence#Efficacy|'''Efficacy''']]
+!style="width: 20%"|Comparator
+!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 |-
-|[http://jco.ascopubs.org/content/19/2/376.long Olsen et al. 2001]
+|[https://doi.org/10.1200/jco.2001.19.2.376 Olsen et al. 2001 (L4389-10)]
-|style="background-color:#00CD00"|Phase III
+|NR
-|Alternate dosing (9 mcg/kg)
+|style="background-color:#1a9851"|Phase 3 (E-RT-esc)
-|style="background-color:#eeee00"|Seems not superior
+|[[#Denileukin_diftitox_monotherapy|Denileukin diftitox]]; 9 mcg/kg
+|style="background-color:#ffffbf"|Did not meet primary endpoint of ORR
 |-
-|rowspan=2|[http://jco.ascopubs.org/content/28/11/1870.long Prince et al. 2010]
+|rowspan=2|[https://doi.org/10.1200/jco.2009.26.2386 Prince et al. 2010 (L4389-11)]
-|rowspan=2 style="background-color:#00CD00"|Phase III
+|rowspan=2|NR
-|Alternate dosing (9 mcg/kg)
+|rowspan=2 style="background-color:#1a9851"|Phase 3 (E-RT-esc)
-|style="background-color:#00CD00"|Superior ORR
+|1. [[#Denileukin_diftitox_monotherapy|Denileukin diftitox]]; 9 mcg/kg
+|style="background-color:#1a9850"|Superior ORR (primary endpoint)
 |-
-|Placebo
+|2. [[Cutaneous_T-cell_lymphoma_-_null_regimens#Placebo_2|Placebo]]
-|style="background-color:#00CD00"|Superior PFS
+|style="background-color:#1a9850"|Superior PFS (secondary endpoint)
 |-
 |}
-''Dose is that which was recommended by Prince et al. 2010 based on superior response.''
+''Note: Dose is that which was recommended in L4389-11 based on superior response. Up to 3 additional cycles allowed in L4389-10 for patients who had ongoing response.''
-====Chemotherapy====
+<div class="toccolours" style="background-color:#b3e2cd">
+====Targeted therapy====
 *[[Denileukin diftitox (Ontak)]] 18 mcg/kg IV over 15 to 60 minutes once per day on days 1 to 5
+====Supportive therapy====
-====Supportive medications====
 *"Premedication with [[Acetaminophen (Tylenol)]] (650 mg in Olsen et al. 2001) and an antihistamine was required 30 to 60 minutes before each infusion" and could be used after infusions as needed.
 *Olsen et al. 2001 used [[Promethazine (Phenergan)]] 25 mg or [[Prochlorperazine (Compazine)]] 10 mg (route/schedule not specified) as needed for nausea.
 *Corticosteroid use was not allowed.
+'''21-day cycles for up to 8 cycles (see note)'''
-'''21-day cycles for up to 8 cycles'''
+</div></div>
-''Up to 3 additional cycles allowed in the Olsen et al. 2001 trial for patients who had ongoing response.''
 ===References===
-# Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E, Jegasothy B, Wood G, Gordon M, Heald P, Oseroff A, Pinter-Brown L, Bowen G, Kuzel T, Fivenson D, Foss F, Glode M, Molina A, Knobler E, Stewart S, Cooper K, Stevens S, Craig F, Reuben J, Bacha P, Nichols J. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol. 2001 Jan 15;19(2):376-88. [http://jco.ascopubs.org/content/19/2/376.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11208829 PubMed]
+# '''L4389-10:''' Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E, Jegasothy B, Wood G, Gordon M, Heald P, Oseroff A, Pinter-Brown L, Bowen G, Kuzel T, Fivenson D, Foss F, Glode M, Molina A, Knobler E, Stewart S, Cooper K, Stevens S, Craig F, Reuben J, Bacha P, Nichols J. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol. 2001 Jan 15;19(2):376-88. [https://doi.org/10.1200/jco.2001.19.2.376 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/11208829/ PubMed]
 <!-- Presented in part at the 43rd Annual Meeting of the American Society of Clinical Oncology, June 1-5, 2007, Chicago, IL; and the 44th Annual Meeting of the American Society of Clinical Oncology, May 30-June 3, 2008, Chicago, IL. -->
-# Prince HM, Duvic M, Martin A, Sterry W, Assaf C, Sun Y, Straus D, Acosta M, Negro-Vilar A. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2010 Apr 10;28(11):1870-7. Epub 2010 Mar 8. [http://jco.ascopubs.org/content/28/11/1870.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20212249 PubMed]
+# '''L4389-11:''' Prince HM, Duvic M, Martin A, Sterry W, Assaf C, Sun Y, Straus D, Acosta M, Negro-Vilar A. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2010 Apr 10;28(11):1870-7. Epub 2010 Mar 8. [https://doi.org/10.1200/jco.2009.26.2386 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/20212249/ PubMed] [https://clinicaltrials.gov/study/NCT00050999 NCT00050999]
-# Duvic M, Martin AG, Olsen EA, Fivenson DP, Prince HM. Efficacy and safety of denileukin diftitox retreatment in patients with relapsed cutaneous T-cell lymphoma. Leuk Lymphoma. 2013 Mar;54(3):514-9. Epub 2012 Sep 3. [http://informahealthcare.com/doi/abs/10.3109/10428194.2012.720372 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22891708 PubMed]
 <!-- Presented in part at the 46th Annual Meeting of the American Society of Clinical Oncology in Chicago, IL, June 4-8, 2010 -->
-# '''Meta-analysis:''' Duvic M, Geskin L, Prince HM. Duration of response in cutaneous T-cell lymphoma patients treated with denileukin diftitox: results from 3 phase III studies. Clin Lymphoma Myeloma Leuk. 2013 Aug;13(4):377-84. Epub 2013 Jun 14. [http://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(13)00095-5/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23770157 PubMed]
+# '''Meta-analysis:''' Duvic M, Geskin L, Prince HM. Duration of response in cutaneous T-cell lymphoma patients treated with denileukin diftitox: results from 3 phase III studies. Clin Lymphoma Myeloma Leuk. 2013 Aug;13(4):377-84. Epub 2013 Jun 14. [https://doi.org/10.1016/j.clml.2013.02.020 link to original article] [https://pubmed.ncbi.nlm.nih.gov/23770157/ PubMed]
-==Lenalidomide (Revlimid) {{#subobject:d48e4c|Regimen=1}}==
+==Lenalidomide monotherapy {{#subobject:d48e4c|Regimen=1}}==
-{| class="wikitable" style="float:right; margin-left: 5px;"
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen {{#subobject:2dd505|Variant=1}}===
+{| class="wikitable" style="width: 60%; text-align:center;"
+!style="width: 33%"|Study
+!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+|-
+|[http://www.bloodjournal.org/content/123/8/1159.full Querfeld et al. 2013 (NU 04H5)]
+|style="background-color:#91cf61"|Phase 2
+| style="background-color:#8c6bb1" |ORR: 28%
 |-
-|[[#top|back to top]]
 |}
+''Note: dose escalations only occurred if the prior dose was tolerated.''
+<div class="toccolours" style="background-color:#b3e2cd">
+====Targeted therapy====
+*[[Lenalidomide (Revlimid)]] as follows:
+**Cycle 1: 10 mg PO once per day on days 1 to 21
+**Cycle 2: 15 mg PO once per day on days 1 to 21
+**Cycle 3: 20 mg PO once per day on days 1 to 21
+**Cycles 4 to 26: 25 mg PO once per day on days 1 to 21
+'''28-day cycle for up to 26 cycles (2 years)'''
+</div></div>
+===References===
+# '''NU 04H5:''' Querfeld C, Rosen ST, Guitart J, Duvic M, Kim YH, Dusza SW, Kuzel TM. Results of an open-label multicenter phase II trial of lenalidomide monotherapy in refractory mycosis fungoides and Sezary syndrome. Blood. 2014 Feb 20;123(8):1159-66. Epub 2013 Dec 11. [http://www.bloodjournal.org/content/123/8/1159.full link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/24335103/ PubMed] [https://clinicaltrials.gov/study/NCT00466921 NCT00466921]
-===Regimen {{#subobject:2dd505|Variant=1}}===
+==Methotrexate monotherapy {{#subobject:0ff378|Regimen=1}}==
-{| border="1" style="text-align:center;" !align="left"
+<div class="toccolours" style="background-color:#eeeeee">
-|'''Study'''
+===Regimen {{#subobject:dfe411|Variant=1}}===
-|[[Levels_of_Evidence#Evidence|'''Evidence''']]
+{| class="wikitable sortable" style="width: 100%; text-align:center;"
+!style="width: 20%"|Study
+!style="width: 20%"|Dates of enrollment
+!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 20%"|Comparator
+!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 |-
-|[http://bloodjournal.hematologylibrary.org/content/123/8/1159.full Querfeld et al. 2013]
+|[https://doi.org/10.1016/S0140-6736(17)31266-7 Prince et al. 2017 (ALCANZA)]
-|style="background-color:#EEEE00"|Phase II
+|2012-2015
+|style="background-color:#1a9851"|Phase 3 (C)
+|[[#Brentuximab_vedotin_monotherapy|Brentuximab vedotin]]
+|style="background-color:#d73027"|Inferior PFS<sup>1</sup>
 |-
 |}
+''<sup>1</sup>Reported efficacy is based on the 2021 update.''<br>
+''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.''
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
-*[[Lenalidomide (Revlimid)]] 10 mg PO once per day on days 1 to 21
+*[[Methotrexate (MTX)]] 5 to 50 mg PO once on day 1
-**Dose increased by 5 mg per day with each cycle to a maximum of 25 mg PO once per day, as tolerated
+'''7-day cycle for 48 cycles'''
+</div></div>
-'''28-day cycle for up to 2 years or until disease progression'''
 ===References===
-# Querfeld C, Rosen ST, Guitart J, Duvic M, Kim YH, Dusza SW, Kuzel TM. Results of an open-label multicenter phase II trial of lenalidomide monotherapy in refractory mycosis fungoides and Sezary syndrome. Blood. 2014 Feb 20;123(8):1159-66. Epub 2013 Dec 11. [http://bloodjournal.hematologylibrary.org/content/123/8/1159.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24335103 PubMed]
+# '''Retrospective:''' Zackheim HS, Kashani-Sabet M, McMillan A. Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients. J Am Acad Dermatol. 2003 Nov;49(5):873-8. [https://www.jaad.org/article/S0190-9622(03)01591-3 link to original article] [https://pubmed.ncbi.nlm.nih.gov/14576667/ PubMed]
+# '''ALCANZA:''' Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Trotman J, Taylor K, Dalle S, Weichenthal M, Walewski J, Fisher D, Dréno B, Stadler R, Feldman T, Kuzel TM, Wang Y, Palanca-Wessels MC, Zagadailov E, Trepicchio WL, Zhang W, Lin HM, Liu Y, Huebner D, Little M, Whittaker S, Duvic M; ALCANZA study group. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017 Aug 5;390(10094):555-566. Epub 2017 Jun 7. [https://doi.org/10.1016/S0140-6736(17)31266-7 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/28600132/ PubMed] [https://clinicaltrials.gov/study/NCT01578499 NCT01578499]
-==Pralatrexate (Folotyn) {{#subobject:1df1c0|Regimen=1}}==
+##'''Update:''' Horwitz SM, Scarisbrick JJ, Dummer R, Whittaker S, Duvic M, Kim YH, Quaglino P, Zinzani PL, Bechter O, Eradat H, Pinter-Brown L, Akilov OE, Geskin L, Sanches JA, Ortiz-Romero PL, Weichenthal M, Fisher DC, Walewski J, Trotman J, Taylor K, Dalle S, Stadler R, Lisano J, Bunn V, Little M, Prince HM. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data. Blood Adv. 2021 Dec 14;5(23):5098-5106. [https://doi.org/10.1182/bloodadvances.2021004710 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9153035/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/34507350/ PubMed]
-{| class="wikitable" style="float:right; margin-left: 5px;"
+==Mogamulizumab monotherapy {{#subobject:8d8ae3|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen variant #1, 8-week course {{#subobject:2848bf|Variant=1}}===
+{| class="wikitable" style="width: 40%; text-align:center;"
+!style="width: 25%"|Study
+!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+|-
+|[https://doi.org/10.1200/jco.2013.52.0924 Ogura et al. 2014 (KW-0761-004)]
+|style="background-color:#91cf61"|Phase 2
+|-
+|}
+<div class="toccolours" style="background-color:#b3e2cd">
+====Targeted therapy====
+*[[Mogamulizumab (Poteligeo)]] 1 mg/kg IV once on day 1
+'''7-day cycle for 8 cycles'''
+</div></div><br>
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen variant #2, indefinite {{#subobject:097b16|Variant=1}}===
+{| class="wikitable" style="color:white; background-color:#404040"
+|<small>'''FDA-recommended dose'''</small>
+|-
+|}
+{| class="wikitable sortable" style="width: 100%; text-align:center;"
+!style="width: 20%"|Study
+!style="width: 20%"|Dates of enrollment
+!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 20%"|Comparator
+!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+|-
+|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4375715/ Duvic et al. 2015 (KW-0761-001)]
+|2009-NR
+|style="background-color:#91cf61"|Phase 1/2
+| style="background-color:#d3d3d3" |
+| style="background-color:#d3d3d3" |
+|-
+|[https://doi.org/10.1016/S1470-2045(18)30379-6 Kim et al. 2018 (MAVORIC)]
+|2012-2016
+| style="background-color:#1a9851" |Phase 3 (E-RT-switch-ooc)
+|[[#Vorinostat_monotherapy|Vorinostat]]
+| style="background-color:#1a9850" |Superior PFS (primary endpoint)
 |-
-|[[#top|back to top]]
 |}
+''Note: in KW-0761-001, a two-week "period of observation" was undertaken after cycle 1.''
+<div class="toccolours" style="background-color:#b3e2cd">
+====Targeted therapy====
+*[[Mogamulizumab (Poteligeo)]] as follows:
+**Cycle 1: 1 mg/kg IV once per day on days 1, 8, 15, 22
+**Cycle 2 onwards: 1 mg/kg IV once per day on days 1 & 15
+'''28-day cycles'''
+</div></div>
+===References===
+# '''KW-0761-004:''' Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, Fujimoto K, Yamamoto K, Miyamoto T, Uike N, Tanimoto M, Tsukasaki K, Ishizawa K, Suzumiya J, Inagaki H, Tamura K, Akinaga S, Tomonaga M, Ueda R. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014 Apr 10;32(11):1157-63. Epub 2014 Mar 10. [https://doi.org/10.1200/jco.2013.52.0924 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/24616310/ PubMed] [https://clinicaltrials.gov/study/NCT01192984 NCT01192984]
+# '''KW-0761-001:''' Duvic M, Pinter-Brown LC, Foss FM, Sokol L, Jorgensen JL, Challagundla P, Dwyer KM, Zhang X, Kurman MR, Ballerini R, Liu L, Kim YH. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood. 2015 Mar 19;125(12):1883-9. Epub 2015 Jan 20. [http://www.bloodjournal.org/content/125/12/1883.long link to original article] '''contains dosing details in abstract''' [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4375715/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/25605368/ PubMed] [https://clinicaltrials.gov/study/NCT00888927 NCT00888927]
+# '''MAVORIC:''' Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M; MAVORIC Investigators. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018 Sep;19(9):1192-1204. Epub 2018 Aug 9. [https://doi.org/10.1016/S1470-2045(18)30379-6 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/30100375/ PubMed] [https://clinicaltrials.gov/study/NCT01728805 NCT01728805]
+==Pralatrexate monotherapy {{#subobject:1df1c0|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:ac3b67|Variant=1}}===
-{| border="1" style="text-align:center;" !align="left"
+{| class="wikitable" style="width: 60%; text-align:center;"
-|'''Study'''
+!style="width: 33%"|Study
-|[[Levels_of_Evidence#Evidence|'''Evidence''']]
+!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
-|[http://bloodjournal.hematologylibrary.org/content/119/18/4115.long Horwitz et al. 2012]
+|[http://www.bloodjournal.org/content/119/18/4115.long Horwitz et al. 2012]
-|style="background-color:#EEEE00"|Phase II
+|style="background-color:#91cf61"|Phase 2
+|style="background-color:#737373; color:white"|RR: 45%
 |-
 |}
-''Dose is that identified as recommended based on de-escalation strategy.''
+''Note: Dose is that identified as recommended based on de-escalation strategy.''
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Pralatrexate (Folotyn)]] 15 mg/m<sup>2</sup> IV push once per day on days 1, 8, 15
+====Supportive therapy====
-====Supportive medications====
 *[[Cyanocobalamin (Vitamin B12)]] 1 mg IM once every 8 to 10 weeks, within 10 weeks of treatment initiation
 *[[Folic acid (Folate)]] 1 mg PO once per day, starting at least 10 days prior to treatment initiation
+'''28-day cycles'''
-'''4-week cycles, given until progression of disease, unacceptable toxicity, or patient/physician preference'''
+</div></div>
 ===References===
-# Horwitz SM, Kim YH, Foss F, Zain JM, Myskowski PL, Lechowicz MJ, Fisher DC, Shustov AR, Bartlett NL, Delioukina ML, Koutsoukos T, Saunders ME, O'Connor OA, Duvic M. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 2012 May 3;119(18):4115-22. Epub 2012 Mar 6. [http://bloodjournal.hematologylibrary.org/content/119/18/4115.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22394596 PubMed]
+# Horwitz SM, Kim YH, Foss F, Zain JM, Myskowski PL, Lechowicz MJ, Fisher DC, Shustov AR, Bartlett NL, Delioukina ML, Koutsoukos T, Saunders ME, O'Connor OA, Duvic M. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 2012 May 3;119(18):4115-22. Epub 2012 Mar 6. [http://www.bloodjournal.org/content/119/18/4115.long link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/22394596/ PubMed]
+==Romidepsin monotherapy {{#subobject:b4c097|Regimen=1}}==
-==Romidepsin (Istodax) {{#subobject:b4c097|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
-{| class="wikitable" style="float:right; margin-left: 5px;"
-|-
-|[[#top|back to top]]
-|}
 ===Regimen {{#subobject:7ef1f5|Variant=1}}===
-{| border="1" style="text-align:center;" !align="left"
+{| class="wikitable sortable" style="width: 80%; text-align:center;"
-|'''Study'''
+!style="width: 25%"|Study
-|[[Levels_of_Evidence#Evidence|'''Evidence''']]
+!style="width: 25%"|Dates of enrollment
+!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
-|[http://jco.ascopubs.org/content/27/32/5410.long Piekarz et al. 2009]
+|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2773225/ Piekarz et al. 2009 (NIH 01-C-0049<sub>CTCL</sub>)]
-|style="background-color:#EEEE00"|Phase II
+|NR
+|style="background-color:#91cf61"|Phase 2 (RT)
+| style="background-color:#8c6bb1" |ORR: 34% (95% CI, 23-46)
 |-
-|[http://jco.ascopubs.org/content/28/29/4485.full Whittaker et al. 2010]
+|[https://doi.org/10.1200/jco.2010.28.9066 Whittaker et al. 2010 (GPI-04-0001)]
-|style="background-color:#EEEE00"|Phase II
+|2005-2007
+|style="background-color:#91cf61"|Phase 2 (RT)
+| style="background-color:#8c6bb1" |ORR: 34% (95% CI, 25-45)
 |-
 |}
-====Chemotherapy====
+<div class="toccolours" style="background-color:#b3e2cd">
+====Targeted therapy====
 *[[Romidepsin (Istodax)]] 14 mg/m<sup>2</sup> IV over 4 hours once per day on days 1, 8, 15
+'''28-day cycle for up to 6 cycles; optional extension of treatment for patients with SD or better'''
-'''28-day cycle for up to 6 cycles, with optional extension of treatment for patients with stable disease or response'''
+</div></div>
 ===References===
-# Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH, Zain J, Prince HM, Leonard JP, Geskin LJ, Reeder C, Joske D, Figg WD, Gardner ER, Steinberg SM, Jaffe ES, Stetler-Stevenson M, Lade S, Fojo AT, Bates SE. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009 Nov 10;27(32):5410-7. Epub 2009 Oct 13. [http://jco.ascopubs.org/content/27/32/5410.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19826128 PubMed]
+# '''NIH 01-C-0049<sub>CTCL</sub>:''' Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH, Zain J, Prince HM, Leonard JP, Geskin LJ, Reeder C, Joske D, Figg WD, Gardner ER, Steinberg SM, Jaffe ES, Stetler-Stevenson M, Lade S, Fojo AT, Bates SE. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009 Nov 10;27(32):5410-7. Epub 2009 Oct 13. [https://doi.org/10.1200/jco.2008.21.6150 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2773225/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/19826128/ PubMed] [https://clinicaltrials.gov/study/NCT00007345 NCT00007345]
-# Whittaker SJ, Demierre MF, Kim EJ, Rook AH, Lerner A, Duvic M, Scarisbrick J, Reddy S, Robak T, Becker JC, Samtsov A, McCulloch W, Kim YH. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010 Oct 10;28(29):4485-91. Epub 2010 Aug 9. [http://jco.ascopubs.org/content/28/29/4485.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20697094 PubMed]
+# '''GPI-04-0001:''' Whittaker SJ, Demierre MF, Kim EJ, Rook AH, Lerner A, Duvic M, Scarisbrick J, Reddy S, Robak T, Becker JC, Samtsov A, McCulloch W, Kim YH. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010 Oct 10;28(29):4485-91. Epub 2010 Aug 9. [https://doi.org/10.1200/jco.2010.28.9066 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/20697094/ PubMed] [https://clinicaltrials.gov/study/NCT00106431 NCT00106431]
-==Vorinostat (Zolinza) {{#subobject:6a3a5b|Regimen=1}}==
+==Vorinostat monotherapy {{#subobject:6a3a5b|Regimen=1}}==
-{| class="wikitable" style="float:right; margin-left: 5px;"
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen {{#subobject:d18568|Variant=1}}===
+{| class="wikitable" style="color:white; background-color:#404040"
+|<small>'''FDA-recommended dose'''</small>
 |-
-|[[#top|back to top]]
 |}
+{| class="wikitable sortable" style="width: 100%; text-align:center;"
-===Regimen {{#subobject:d18568|Variant=1}}===
+!style="width: 20%"|Study
-{| border="1" style="text-align:center;" !align="left"
+!style="width: 20%"|Dates of enrollment
-|'''Study'''
+!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
-|[[Levels_of_Evidence#Evidence|'''Evidence''']]
+!style="width: 20%"|Comparator
+!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+|-
+|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1785068/ Duvic et al. 2006]
+|NR
+|style="background-color:#91cf61"|Phase 2a (RT)
+| style="background-color:#d3d3d3" |
+| style="background-color:#88419d; color:white |ORR: 24%
+|-
+|[https://doi.org/10.1200/jco.2006.10.2434 Olsen et al. 2007 (Merck 0683-001)]
+|NR
+|style="background-color:#91cf61"|Phase 2b (RT)
+| style="background-color:#d3d3d3" |
+| style="background-color:#8c6bb1" |ORR: 30%
 |-
-|[http://jco.ascopubs.org/content/25/21/3109.full Olsen et al. 2007]
+|[https://doi.org/10.1016/S1470-2045(18)30379-6 Kim et al. 2018 (MAVORIC)]
-|style="background-color:#EEEE00"|Phase II
+|2012-2016
+| style="background-color:#1a9851" |Phase 3 (C)
+|[[#Mogamulizumab_monotherapy|Mogamulizumab]]
+| style="background-color:#d73027" |Inferior PFS
 |-
 |}
-====Chemotherapy====
+''Note: Duvic et al. 2006 evaluated several different doses, but this is the one that "had the most favorable safety profile". To our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.''
+<div class="toccolours" style="background-color:#b3e2cd">
+====Targeted therapy====
 *[[Vorinostat (Zolinza)]] 400 mg PO once per day
+'''Continued indefinitely'''
+</div></div>
+===References===
+# Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VM, Frankel SR. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007 Jan 1;109(1):31-9. Epub 2006 Sep 7. Erratum in: Blood. 2007 Jun 15;109(12):5086. [http://www.bloodjournal.org/content/109/1/31.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1785068/ link to PMC article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/16960145/ PubMed]
+# '''Merck 0683-001:''' Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM, Duvic M. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007 Jul 20;25(21):3109-15. Epub 2007 Jun 18. [https://doi.org/10.1200/jco.2006.10.2434 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/17577020/ PubMed] [https://clinicaltrials.gov/study/NCT00091559 NCT00091559]
+## '''Update:''' Duvic M, Olsen EA, Breneman D, Pacheco TR, Parker S, Vonderheid EC, Abuav R, Ricker JL, Rizvi S, Chen C, Boileau K, Gunchenko A, Sanz-Rodriguez C, Geskin LJ. Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma. Clin Lymphoma Myeloma. 2009 Dec;9(6):412-6. [https://doi.org/10.3816/clm.2009.n.082 link to original article] [https://pubmed.ncbi.nlm.nih.gov/19951879/ PubMed]
+# '''MAVORIC:''' Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M; MAVORIC Investigators. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018 Sep;19(9):1192-1204. Epub 2018 Aug 9. [https://doi.org/10.1016/S1470-2045(18)30379-6 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/30100375/ PubMed] [https://clinicaltrials.gov/study/NCT01728805 NCT01728805]
-'''Continued until disease progression or intolerable toxicity'''
+=Relapsed or refractory, subsequent lines of treatment=
+==Denileukin diftitox monotherapy {{#subobject:bf44d8|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen {{#subobject:3a3d12|Variant=1}}===
+{| class="wikitable" style="width: 40%; text-align:center;"
+!style="width: 25%"|Study
+!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+|-
+|[https://doi.org/10.3109/10428194.2012.720372 Duvic et al. 2012]
+| style="background-color:#91cf61" |Non-randomized
+|-
+|}
+<div class="toccolours" style="background-color:#b3e2cd">
+====Targeted therapy====
+*[[Denileukin diftitox (Ontak)]] 18 mcg/kg IV once per day on days 1 to 5
+'''21-day cycle for up to 8 cycles'''
+</div></div>
+===References===
+# Duvic M, Martin AG, Olsen EA, Fivenson DP, Prince HM. Efficacy and safety of denileukin diftitox retreatment in patients with relapsed cutaneous T-cell lymphoma. Leuk Lymphoma. 2013 Mar;54(3):514-9. Epub 2012 Sep 3. [https://doi.org/10.3109/10428194.2012.720372 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/22891708/ PubMed]
+=Consolidation, all lines of therapy=
+==Busulfan & Fludarabine, then allo HSCT {{#subobject:3fe0f0|Regimen=1}}==
+BuFlu: '''<u>Bu</u>'''sulfan & '''<u>Flu</u>'''darabine
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen {{#subobject:a7e574|Variant=1}}===
+{| class="wikitable sortable" style="width: 100%; text-align:center;"
+!style="width: 20%"|Study
+!style="width: 20%"|Dates of enrollment
+!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 20%"|Comparator
+!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+|-
+|[https://doi.org/10.1016/s0140-6736(23)00329-x de Masson et al. 2023 (CUTALLO)]
+|2016-06-01 to 2022-03-03
+| style="background-color:#1a9851" |Propensity score analysis (E-esc)
+|No transplant
+| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 9 vs 3 mo<br>(HR 0.38, 95% CI 0.21-0.69)
+|-
+|}
+{{#lst:Allogeneic HSCT|a7ehw4}}
+</div></div>
 ===References===
-# Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM, Duvic M. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007 Jul 20;25(21):3109-15. [http://jco.ascopubs.org/content/25/21/3109.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17577020 PubMed]
+#'''CUTALLO:''' de Masson A, Beylot-Barry M, Ram-Wolff C, Mear JB, Dalle S, d'Incan M, Ingen-Housz-Oro S, Orvain C, Abraham J, Dereure O, Charbonnier A, Cornillon J, Longvert C, Barete S, Boulinguez S, Wierzbicka-Hainaut E, Aubin F, Rubio MT, Bernard M, Schmidt-Tanguy A, Houot R, Pham-Ledard A, Michonneau D, Brice P, Labussière-Wallet H, Bouaziz JD, Grange F, Moins-Teisserenc H, Jondeau K, Michel L, Mourah S, Battistella M, Daguindau E, Loschi M, Picard A, Franck N, Maillard N, Huynh A, Nguyen S, Marçais A, Chaby G, Ceballos P, Le Corre Y, Maury S, Bay JO, Adamski H, Bachy E, Forcade E, Socié G, Bagot M, Chevret S, Peffault de Latour R; CUTALLO Investigators; Groupe Français d'Etude des Lymphomes Cutanés; Société Française de Greffe de Moëlle et Thérapie Cellulaire. Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study. Lancet. 2023 Jun 10;401(10392):1941-1950. Epub 2023 Apr 24. [https://doi.org/10.1016/s0140-6736(23)00329-x link to original article] '''contains dosing details in supplement''' [https://pubmed.ncbi.nlm.nih.gov/37105210/ PubMed] [https://clinicaltrials.gov/study/NCT02520908 NCT02520908]
-=Investigational agents=
+==Busulfan, Fludarabine, Thiotepa, then allo HSCT {{#subobject:3ogjc3|Regimen=1}}==
-''These are drugs under study with at least some promising results for this disease.''
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen {{#subobject:iyrc24|Variant=1}}===
+{| class="wikitable sortable" style="width: 100%; text-align:center;"
+!style="width: 20%"|Study
+!style="width: 20%"|Dates of enrollment
+!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 20%"|Comparator
+!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+|-
+|[https://doi.org/10.1016/s0140-6736(23)00329-x de Masson et al. 2023 (CUTALLO)]
+|2016-06-01 to 2022-03-03
+| style="background-color:#1a9851" |Propensity score analysis (E-esc)
+|No transplant
+| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 9 vs 3 mo<br>(HR 0.38, 95% CI 0.21-0.69)
+|-
+|}
+{{#lst:Allogeneic HSCT|iyrc24}}
+</div></div>
+===References===
+#'''CUTALLO:''' de Masson A, Beylot-Barry M, Ram-Wolff C, Mear JB, Dalle S, d'Incan M, Ingen-Housz-Oro S, Orvain C, Abraham J, Dereure O, Charbonnier A, Cornillon J, Longvert C, Barete S, Boulinguez S, Wierzbicka-Hainaut E, Aubin F, Rubio MT, Bernard M, Schmidt-Tanguy A, Houot R, Pham-Ledard A, Michonneau D, Brice P, Labussière-Wallet H, Bouaziz JD, Grange F, Moins-Teisserenc H, Jondeau K, Michel L, Mourah S, Battistella M, Daguindau E, Loschi M, Picard A, Franck N, Maillard N, Huynh A, Nguyen S, Marçais A, Chaby G, Ceballos P, Le Corre Y, Maury S, Bay JO, Adamski H, Bachy E, Forcade E, Socié G, Bagot M, Chevret S, Peffault de Latour R; CUTALLO Investigators; Groupe Français d'Etude des Lymphomes Cutanés; Société Française de Greffe de Moëlle et Thérapie Cellulaire. Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study. Lancet. 2023 Jun 10;401(10392):1941-1950. Epub 2023 Apr 24. [https://doi.org/10.1016/s0140-6736(23)00329-x link to original article] '''contains dosing details in supplement''' [https://pubmed.ncbi.nlm.nih.gov/37105210/ PubMed] [https://clinicaltrials.gov/study/NCT02520908 NCT02520908]
-*[[Mogamulizumab (KW-0761)]]
+==Fludarabine & Melphalan, then allo HSCT {{#subobject:3fe0f0|Regimen=1}}==
+FluMel: '''<u>Flu</u>'''darabine & '''<u>Mel</u>'''phalan
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen {{#subobject:ojnvwc|Variant=1}}===
+{| class="wikitable sortable" style="width: 100%; text-align:center;"
+!style="width: 20%"|Study
+!style="width: 20%"|Dates of enrollment
+!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 20%"|Comparator
+!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+|-
+|[https://doi.org/10.1016/s0140-6736(23)00329-x de Masson et al. 2023 (CUTALLO)]
+|2016-06-01 to 2022-03-03
+| style="background-color:#1a9851" |Propensity score analysis (E-esc)
+|No transplant
+| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 9 vs 3 mo<br>(HR 0.38, 95% CI 0.21-0.69)
+|-
+|}
+{{#lst:Allogeneic HSCT|ojnvwc}}
+</div></div>
+===References===
+#'''CUTALLO:''' de Masson A, Beylot-Barry M, Ram-Wolff C, Mear JB, Dalle S, d'Incan M, Ingen-Housz-Oro S, Orvain C, Abraham J, Dereure O, Charbonnier A, Cornillon J, Longvert C, Barete S, Boulinguez S, Wierzbicka-Hainaut E, Aubin F, Rubio MT, Bernard M, Schmidt-Tanguy A, Houot R, Pham-Ledard A, Michonneau D, Brice P, Labussière-Wallet H, Bouaziz JD, Grange F, Moins-Teisserenc H, Jondeau K, Michel L, Mourah S, Battistella M, Daguindau E, Loschi M, Picard A, Franck N, Maillard N, Huynh A, Nguyen S, Marçais A, Chaby G, Ceballos P, Le Corre Y, Maury S, Bay JO, Adamski H, Bachy E, Forcade E, Socié G, Bagot M, Chevret S, Peffault de Latour R; CUTALLO Investigators; Groupe Français d'Etude des Lymphomes Cutanés; Société Française de Greffe de Moëlle et Thérapie Cellulaire. Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study. Lancet. 2023 Jun 10;401(10392):1941-1950. Epub 2023 Apr 24. [https://doi.org/10.1016/s0140-6736(23)00329-x link to original article] '''contains dosing details in supplement''' [https://pubmed.ncbi.nlm.nih.gov/37105210/ PubMed] [https://clinicaltrials.gov/study/NCT02520908 NCT02520908]
 [[Category:Cutaneous T-cell lymphoma regimens]]
 [[Category:Disease-specific pages]]
-[[Category:Disease index]]
+[[Category:Cutaneous lymphomas]]
+[[Category:T-cell lymphomas]]

Difference between revisions of "Cutaneous T-cell lymphoma"

Revision as of 12:12, 23 June 2024

Guidelines

ESMO

NCCN

Upfront therapy

PUVA

Regimen

Chemotherapy

References

Topical therapy

Regimen

References

Relapsed or refractory

Alemtuzumab monotherapy

Regimen

Targeted therapy

References

Belinostat monotherapy

Regimen

Targeted therapy

References

Bendamustine monotherapy

Regimen

Chemotherapy

References

Bexarotene monotherapy

Regimen variant #1, 48 weeks

Targeted therapy

Regimen variant #2, indefinite

Targeted therapy

References

Bexarotene & Pralatrexate

Regimen

Targeted therapy

Chemotherapy

References

Brentuximab vedotin monotherapy

Regimen

Antibody-drug conjugate therapy

References

Denileukin diftitox monotherapy

Regimen

Targeted therapy

Supportive therapy

References

Lenalidomide monotherapy

Regimen

Targeted therapy

References

Methotrexate monotherapy

Regimen

Chemotherapy

References

Mogamulizumab monotherapy

Regimen variant #1, 8-week course

Targeted therapy

Regimen variant #2, indefinite

Targeted therapy

References

Pralatrexate monotherapy

Regimen

Chemotherapy

Supportive therapy

References

Romidepsin monotherapy

Regimen

Targeted therapy

References

Vorinostat monotherapy

Regimen

Targeted therapy

References

Relapsed or refractory, subsequent lines of treatment

Denileukin diftitox monotherapy

Regimen

Targeted therapy

References

Consolidation, all lines of therapy

Busulfan & Fludarabine, then allo HSCT